Latent Autoimmune Diabetes in Adults (LADA) is a type of diabetes that develops in adults. It's similar to type 1 diabetes, but it usually happens more slowly. The body's immune system attacks the insulin-producing cells in the pancreas. This leads to high blood sugar levels over time. It's often called type 1.5 diabetes.
Every report comes from a Lived member, sent anonymously.
Have you tried Lantus (Insulin Glargine) for Latent Autoimmune Diabetes in Adults?
Latent autoimmune diabetes in adults (LADA), sometimes called type 1.5 diabetes, is a slowly developing form of autoimmune diabetes. As in type 1 diabetes, the immune system gradually damages the cells in the pancreas that make insulin, the hormone that moves sugar from the blood into the body's cells. The difference is pace. In LADA the damage unfolds over months to years, so at diagnosis the pancreas still makes enough insulin that the person does not need insulin injections. Because it appears in adulthood and can be managed at first without insulin, LADA is often diagnosed as type 2 diabetes. That matters because the two follow different paths: type 2 diabetes is driven mainly by the body responding poorly to insulin, while LADA tends to move steadily toward insulin deficiency. Recognizing it lets treatment keep pace with that change. The American Diabetes Association groups LADA within type 1 diabetes, but the name remains widely used.
LADA happens when the immune system targets the pancreas's insulin-producing cells. Why this begins in adulthood is not well understood. It shares inherited risk genes with type 1 diabetes, and a personal or family history of autoimmune conditions, such as thyroid disease, makes it more likely. Factors linked with type 2 diabetes also appear to play a part, including excess weight, physical inactivity, smoking and drinking sweetened beverages. These are associations seen in studies, mostly from Scandinavia, rather than proven causes, and nothing a person did is known to have triggered the autoimmune process. Estimates suggest LADA accounts for roughly 2 to 12 percent of adults with diabetes, depending on the population and how it is tested.
The first step is diagnosing diabetes itself. In the United States, diabetes is usually confirmed by an A1C (a blood test reflecting average blood sugar over about three months) of 6.5% or higher, or a fasting blood sugar of 126 mg/dL or higher, generally on two tests unless sugar is unmistakably high. LADA is then identified with blood tests for islet autoantibodies, immune proteins aimed at the pancreas. The most common is the GAD antibody (glutamic acid decarboxylase antibody). A positive antibody test in an adult whose diabetes did not need insulin for at least the first six months points to LADA. Clinicians are more likely to check when someone is younger or leaner than is typical for type 2 diabetes, has a personal or family history of autoimmune disease, or finds that blood sugar stays hard to control despite usual treatment. There is no single defining test, and a single antibody result can occasionally be falsely positive, so confirmation with more specific or additional antibody tests helps. A C-peptide blood test is often added. C-peptide is released in equal amounts with the body's own insulin, so it estimates how much insulin the pancreas is still making. That level, rather than the label alone, does most to guide treatment.
Treatment aims to keep blood sugar in a healthy range and, where possible, protect the insulin production that remains. No large, long-term trials have defined the best approach, so recommendations come mainly from small studies and an international expert consensus, and plans are tailored to how much insulin a person still makes. When C-peptide is low, insulin is the main treatment, often with several daily doses as in type 1 diabetes. It is effective and safe, but it requires blood sugar monitoring and brings a risk of low blood sugar. Whether starting insulin early helps preserve the pancreas is still uncertain. When insulin production is still substantial, care looks more like type 2 diabetes treatment, with regular rechecking. Metformin, a common first medicine for type 2 diabetes, is often already in use and is reasonable to continue. DPP-4 inhibitors (tablets such as sitagliptin) and GLP-1 receptor agonists (injectable medicines such as dulaglutide) have improved blood sugar in small studies, though GLP-1 medicines help less once insulin production is very low. Two cautions are specific to LADA. Sulfonylureas, older tablets such as glyburide or glimepiride that push the pancreas to release more insulin, are not recommended by the expert panel because they may speed the loss of insulin-making cells. SGLT2 inhibitors, which lower blood sugar by passing more of it into the urine, can trigger diabetic ketoacidosis in people with low insulin production, sometimes while glucose readings look only modestly raised, so people taking them may be asked to check ketones. Healthy eating, regular activity, weight loss when appropriate and stopping smoking support any medication plan. Treatments that calm the immune attack itself remain experimental for LADA.
LADA usually changes over time. Many people manage well for a period with lifestyle measures and tablets, but insulin production tends to decline, and most eventually need insulin. In one large British study, at least half of people with LADA were using insulin within six years, while some still did not need it after ten. The pace varies with age at diagnosis and with antibody results: people with high GAD antibody levels or more than one type of antibody tend to need insulin sooner. Regular follow-up is how the plan keeps up with these changes. Expect periodic A1C tests, and repeat C-peptide testing when blood sugar control slips, at least every six months when insulin production is in a middle range. Moving to insulin is an expected step in LADA, not a sign that someone managed their diabetes poorly. The long-term health risks are those of diabetes in general. Keeping blood sugar, blood pressure and cholesterol in range lowers the risk of heart disease and damage to the eyes, kidneys and nerves. Because LADA is autoimmune, thyroid problems and other autoimmune conditions are also more common, so it is worth discussing whether checks such as a thyroid blood test belong in your follow-up.
Ask about antibody testing if you have been diagnosed with type 2 diabetes and blood sugar keeps rising despite treatment, especially if you are not overweight or have a personal or family history of autoimmune disease. Contact your care team soon if your readings climb steadily or you notice increasing thirst, frequent urination or unexplained weight loss, since these can mean your body is making less insulin and your treatment needs to change. Diabetic ketoacidosis (DKA), a dangerous buildup of acids called ketones when the body lacks insulin, needs urgent care. If you have moderate or high ketones on a home test, or symptoms such as nausea or vomiting, belly pain, trouble breathing, confusion or unusual drowsiness, contact your care team right away or get emergency medical help. This applies even if your glucose reading is not very high, especially if you take an SGLT2 inhibitor.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Latent Autoimmune Diabetes in Adults is like, what's helped you, or ask the community a question.